140 related articles for article (PubMed ID: 2878607)
1. Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers.
Levendoglu H; Mehta B; Wait C; Reddy G; Hatcher C
Am J Gastroenterol; 1986 Dec; 81(12):1167-70. PubMed ID: 2878607
[TBL] [Abstract][Full Text] [Related]
2. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration.
Pace F; Colombo E; Ferrara A; Prada A; Rocca F; Bianchi Porro G
Am J Gastroenterol; 1988 Jun; 83(6):643-5. PubMed ID: 2897784
[TBL] [Abstract][Full Text] [Related]
3. Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group.
Cherner JA; Cloud ML; Offen WW; Latz JE
Am J Gastroenterol; 1989 Jul; 84(7):769-74. PubMed ID: 2568086
[TBL] [Abstract][Full Text] [Related]
4. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
Lima M; Holdcroft C
Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655
[TBL] [Abstract][Full Text] [Related]
5. Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study.
Bovero E; Poletti M; Boero A; Mura BC; Camarri E; Corradini P; Corsini G; Federici G; Curzio M; Gianquinto G
Hepatogastroenterology; 1987 Dec; 34(6):269-71. PubMed ID: 2892768
[TBL] [Abstract][Full Text] [Related]
6. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
Kuipers EJ; Hazenberg HJ; Quik RF; Hazenberg BP; de Zwart PA
Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy and safety of ebrotidine in the treatment of duodenal ulcer. A multicentre, double-blind, placebo-controlled phase II study.
Gabryelewicz A; Czajkowski A; Skrodzka D; Marlicz K; Luca de Tena F; Aldeguer M; Chantar C; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):545-50. PubMed ID: 9205762
[TBL] [Abstract][Full Text] [Related]
8. [Nizatidine].
Romero M; Franzosi MG
Medicina (Firenze); 1989; 9(1):93-6. PubMed ID: 2567957
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study.
Di Mario F; Battaglia G; Naccarato R; D'Angelo A; Saggioro A; Da Broi GL; Vezzadini P; Bianchi Porro G
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():62-5. PubMed ID: 1982108
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal roxatidine in the treatment of active duodenal ulcer disease. Multicenter Roxatidine Cooperative Study Group.
Gilinsky NH; Bright-Asare P; Cobert BL; Fitch DD; Lanza FL; Kerr RM; Savitsky JP
Am J Gastroenterol; 1992 Jul; 87(7):847-53. PubMed ID: 1352083
[TBL] [Abstract][Full Text] [Related]
11. Nizatidine (AXID).
Med Lett Drugs Ther; 1988 Aug; 30(772):77-8. PubMed ID: 2899835
[No Abstract] [Full Text] [Related]
12. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
Savarino V; Mela GS; Zentilin P; Sumberaz A; Bonifacino G; Celle G
Am J Gastroenterol; 1991 Mar; 86(3):281-4. PubMed ID: 1671805
[TBL] [Abstract][Full Text] [Related]
13. Healing and recurrence of active duodenal ulcer with nizatidine.
Cloud ML; Offen WW; Matsumoto C; Chernish SM
Clin Pharmacol Ther; 1989 Sep; 46(3):310-6. PubMed ID: 2570656
[TBL] [Abstract][Full Text] [Related]
14. Placebo controlled studies with ranitidine in duodenal ulcer.
Dobrilla G; Barbara L; Bianchi Porro G; Felder M; Mazzacca G; Miglioli L; Pera A; Petrillo M; Sabbatini F; Verme G
Scand J Gastroenterol Suppl; 1981 Jun; 69():101-7. PubMed ID: 6119771
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of duodenal ulcer with famotidine].
Schütze K; Hentschel E; Reichel W; Kerstan E
Wien Med Wochenschr; 1987 Sep; 137(17):409-11. PubMed ID: 2891224
[TBL] [Abstract][Full Text] [Related]
16. [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
Baglioni A; Barbara L; Bianchi-Porro G; Blasi A; Canelli B; Cheli R; Dal Monte R; Dammann HG; Francavilla A; Hentschel E
Z Gastroenterol; 1985 Dec; 23(12):665-9. PubMed ID: 2868581
[TBL] [Abstract][Full Text] [Related]
17. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe.
Simon B; Cremer M; Dammann HG; Hentschel E; Keohane PP; Mulder H; Müller P; Sarles H
Scand J Gastroenterol Suppl; 1987; 136():61-70. PubMed ID: 2892257
[TBL] [Abstract][Full Text] [Related]
18. Nizatidine as maintenance therapy of duodenal ulcer disease in remission.
Cerulli MA; Cloud ML; Offen WW; Chernish SM; Matsumoto C
Scand J Gastroenterol Suppl; 1987; 136():79-83. PubMed ID: 2892259
[TBL] [Abstract][Full Text] [Related]
19. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of acute stomach ulcer with H2 receptor antagonists. A direct therapy comparison with 300 mg nizatidine nightly and 2 times 150 mg nizatidine with twice daily 150 mg ranitidine].
Arnold R; Beckenbach P; Bock H; Bormann R; Brunner G; Daake H; Dammann HG; Dietrich K; Fuerer M; Geiter B
Fortschr Med; 1989 Jun; 107(17):390-4. PubMed ID: 2568327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
